10 February 2026 - KPBMA demands postponement, impact assessments, and policy dialogue to protect R&D and health security amid pricing reforms.

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) on the 10th strongly expressed concerns over the government’s ongoing policy to reduce prices of domestically produced specialized generic drugs and urged a postponement of its implementation. The association announced that its board of directors held a meeting on the 10th and unanimously adopted a resolution outlining these demands.

Read Chosun Biz article